Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis.

TitleMetabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis.
Publication TypeJournal Article
Year of Publication2014
AuthorsValencia T, Kim JYoung, Abu-Baker S, Moscat-Pardos J, Ahn CS, Reina-Campos M, Duran A, Castilla EA, Metallo CM, Diaz-Meco MT, Moscat J
JournalCancer Cell
Volume26
Issue1
Pagination121-135
Date Published2014 Jul 14
ISSN1878-3686
KeywordsAdaptor Proteins, Signal Transducing, Amino Acids, Animals, Cell Communication, Cell Line, Tumor, Cell Transformation, Neoplastic, Coculture Techniques, Energy Metabolism, Fibroblasts, Glucose, Heat-Shock Proteins, HEK293 Cells, Humans, Inflammation, Inflammation Mediators, Interleukin-6, Male, Mechanistic Target of Rapamycin Complex 1, Mice, Mice, Inbred C57BL, Mice, Knockout, Multiprotein Complexes, Neoplasm Invasiveness, Oxidative Stress, Prostatic Hyperplasia, Prostatic Intraepithelial Neoplasia, Prostatic Neoplasms, Proto-Oncogene Proteins c-myc, PTEN Phosphohydrolase, RNA Interference, Sequestosome-1 Protein, Signal Transduction, Stromal Cells, Time Factors, TOR Serine-Threonine Kinases, Transfection, Tumor Microenvironment
Abstract

The tumor microenvironment plays a critical role in cancer progression, but the precise mechanisms by which stromal cells influence the epithelium are poorly understood. Here we show that p62 levels were reduced in the stroma of several tumors and that its loss in the tumor microenvironment or stromal fibroblasts resulted in increased tumorigenesis of epithelial prostate cancer cells. The mechanism involves the regulation of cellular redox through an mTORC1/c-Myc pathway of stromal glucose and amino acid metabolism, resulting in increased stromal IL-6 production, which is required for tumor promotion in the epithelial compartment. Thus, p62 is an anti-inflammatory tumor suppressor that acts through the modulation of metabolism in the tumor stroma.

DOI10.1016/j.ccr.2014.05.004
Alternate JournalCancer Cell
PubMed ID25002027
PubMed Central IDPMC4101061
Grant ListR01CA134530 / CA / NCI NIH HHS / United States
R01CA132847 / CA / NCI NIH HHS / United States
5P30CA030199 / CA / NCI NIH HHS / United States
R01CA172025 / CA / NCI NIH HHS / United States
Related Faculty: 
Jorge Moscat, Ph.D. Maria Diaz-Meco Conde, Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700